PT Darya-Varia Laboratoria Tbk (DVL) is one of Indonesia’s leading pharmaceutical companies, specializing in prescription drugs, consumer health products, and export/toll manufacturing. Established in 1976, DVL was the first company in Indonesia to manufacture soft gelatin capsules. Today, its products are widely available across Asia, including the Philippines, Singapore, Malaysia, Vietnam, Myanmar, and Mongolia. The company went public in 1994, listing on the Jakarta Stock Exchange, further cementing its position in the pharmaceutical industry.
Resilient Market Presence and Pandemic Response
DVL’s flagship vitamin brands, Enervon C, Natur-E, and Vicee, remained dominant throughout the COVID-19 pandemic, even strengthening their brand health tracking scores in 2020. As health priorities shifted during the crisis, the company pivoted its focus toward immunity boosters and antiviral treatments. By the end of 2020, DVL accelerated the import of Remdesivir (Remidia), a WHO-recommended antiviral drug, supporting the Indonesian government in treating critical COVID-19 patients.
Despite disruptions in global supply chains and challenges in local toll manufacturing for prescription and cough medications, DVL remained steadfast in its commitment to public health. The company distributed care kits—including PPE, masks, vitamins, and hand sanitizers—to thousands of healthcare professionals while donating medical supplies through government agencies and professional organizations.
During large-scale social lockdowns, DVL took proactive measures to safeguard its employees. The company provided transportation support for essential workers, implemented routine COVID-19 testing, and supplied safety gear, vitamins, and groceries to ensure their well-being.
Digital Expansion and Sustainability Initiatives
Recognizing the growing importance of digital platforms, DVL expanded its presence in e-commerce and online marketplaces to improve public access to its consumer health products. As part of its commitment to sustainability, the company integrates Corporate Social Responsibility initiatives into its daily operations.
Both of DVL’s manufacturing plants, located in Gunung Putri and Citeureup, West Java, operate under strict environmental standards. The company runs a water harvesting program using refill wells and converts domestic waste into fertilizer, which is then donated to surrounding communities.
DVL maintains its reputation for quality by adhering to Good Manufacturing Practices set by the Pharmaceutical Inspection Co-operation Scheme and the Indonesian National Drug and Food Control Agency.
Commitment to Equality and Community Welfare
DVL upholds inclusivity in the workplace by providing job opportunities without discrimination based on gender, ethnicity, religion, race, social status, or physical conditions. More than 52 percent of the company’s permanent employees and nearly half of its top executives are women, reflecting its commitment to diversity and equal opportunity.
Dedicated to building a healthier Indonesia, DVL launched the Sehat Indonesiaku campaign, which promotes equal access to healthcare. Through initiatives like the Healthy Village and Stunting Prevention programs, the company actively supports public health and nutrition.
In partnership with the SOS Children’s Village Foundation, DVL disseminates health information and offers free medical check-ups for children. The company also provides humanitarian aid to disaster-stricken regions and makes annual donations to orphanages.
Recognition and Industry Impact
DVL’s dedication to healthcare and corporate responsibility has earned it numerous accolades, including multiple WOW Brand Awards for its products and Infobrand’s Top Corporate Award for 2020 in recognition of its CSR efforts.
By maintaining its market leadership while prioritizing community well-being, DVL continues to set a benchmark in the Indonesian healthcare industry. Even amid the challenges of the COVID-19 pandemic, the company remained steadfast in its mission—supporting frontliners, ensuring product availability, and safeguarding public health.
